Session Details

U047 Blood Testing for Skin Cancers: Updates on the Use of Liquid Biopsies in Cutaneous Oncology

Sun, Mar 21, 8:00 AM - 9:00 AM
1 CME Available Focus Session NEW

DESCRIPTION

The development and implementation of novel circulating tumor “liquid biopsies” in clinical practice has revolutionized cancer care. These tools provide sensitive and specific analysis of tumor status which enable non-invasive alternatives to tissue biopsy for real-time tumor monitoring, guided targeted therapy, predicted treatment response, and assessing therapeutic resistance and minimal residual disease (MRD). This session highlights state-of-the-art liquid biopsy tools currently in practice with an emphasis on the development and implementation of circulating biomarkers in skin cancers. It is anticipated that liquid biopsy tools will soon become integrated into evolving standards-of-care for improved management of patients with aggressive cutaneous malignancies

LEARNING OBJECTIVES

1.

Describe the latest technologies being used to evaluate skin cancer status from peripheral blood.

2.

Examine current evidence for the use of liquid biopsy techniques in the management of patients with Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel cell carcinoma, Basal Cell Carcinoma and Cutaneous T Cell Lymphoma.

3.

Discuss future directions for liquid biopsy technologies in cutaneous malignancies and their integration into clinical practice.

DIRECTOR

Rhoda Myra Alani, MD, FAAD

Rhoda Myra Alani, MD, FAAD

Brigham and Women's Hospital/Harvard Medical School

SPEAKERS

David Miller, MD, PhD, FAAD

David Miller, MD, PhD, FAAD

Meghan Mooradian, MD

Meghan Mooradian, MD

Hillary C. Tsibris, MD, FAAD

Hillary C. Tsibris, MD, FAAD

Brigham and Women's Hospital, Harvard Medical School

DISCLOSURES

Rhoda Myra Alani, MD, FAAD

No financial relationships exist with ineligible companies.

David Miller, MD, PhD, FAAD

Almirall – Consultant (1099 relationship)(Fees); Avstera Therapeutics Corp – Advisory Board(Stock Options); Bristol Myers Squibb – Consultant (1099 relationship)(Fees); Castle Biosciences – Advisory Board(Fees); Checkpoint Therapeutics – Advisory Board(Honoraria), Advisory Board(Stock Options); Kartos Therapeutics – Investigator(Grants/Research Funding); Merck – Advisory Board(Honoraria); NeoImmuneTech – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria); Xilio Therapeutics – Investigator(Grants/Research Funding);

Hillary C. Tsibris, MD, FAAD

Merck – Advisory Board(Fees);